



Pharmaceuticals, Inc.

Bari Gabbitas
Director, Operations

September 6, 2005

Docket No. 03035426
Control No. 137429
License No. 06-30583-01

MS16
K-4

2005 SEP -9 PM 1:49

RECEIVED
SEP 11 2005

Steven Courtemanche
Health Physicist
Commercial and R&D Branch
Division of Nuclear Materials Safety
Nuclear Regulatory Commission
Region I
475 Allendale Road
King of Prussia, PA 09406-1415

Dear Mr. Courtemanche:

I am writing in response to your letter dated August 23, 2005, regarding our request to amend Nuclear Regulatory Commission License No. 06-30583-01. You have requested clarification on several points as follows:

1. Regarding the change in the name of the company to CGI Pharmaceuticals, Inc.: The company began as a technology company but has since moved its focus to pharmaceutical development. Coinciding with the announcement of our first pharmaceutical clinical development candidate, the name of the company was changed to CGI Pharmaceuticals, Inc. (CGI). The management and Board of Directors at CGI believe that this name change will project a better image as we seek to develop collaborative partnerships in the pharmaceutical industry. The company is now, and has always been, privately funded by venture capital. Ownership of the company has not changed.
2. We wish to delete Changqing Wang, Ph.D. as a named user on our license as he is no longer employed by CGI. We do not wish to add any additional named users at this time.
3. As per your suggestion, we have reviewed the procedure for surveys found in NUREG-1556, Volume 7, Appendix Q. We would like to adopt these guidelines into our program in place of other guidelines or specifications effective immediately.

137429

NUCLEAR MATERIALS-002

Thank you for your assistance with this proposed amendment. Please contact me directly if you have any additional questions or concerns.

Sincerely,

A handwritten signature in cursive script that reads "Bari Gabbitas".

Bari Gabbitas
Director, Operations
Radiation Safety Officer